Shire gains a delayed FDA OK for ‘blockbuster’ dry eye drug lifitegrast
Nine months after the FDA handed Shire $SHPG a rejection for its dry eye drug lifitegrast, the biotech company says it’s bounced back
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
